Sonablate Corp.

LONDON--( BUSINESS WIRE )--The UK Focused Ultrasound Foundation (UK FUSF), dedicated to advancing the development and adoption of focused ultrasound in the UK, today announced its formal launch. Focused ultrasound is a groundbreaking platform technology that uses ultrasound energy guided by real-time imaging to treat tissue deep in the body, without incisions or radiation. The Foundation will celebrate its launch with an event being held on 31 January at the House of Lords with important guests including MPs, members of the House of Lords, business leaders, and experts from medical charities and some of the UK’s leading research institutions, including the Institute of Cancer Research, Oxford University, and Imperial, King’s and University Colleges, London. Currently, focused ultrasound treatment for both prostate cancer and essential tremor has National Institute for Health and Care Excellence (NICE) approval and National Health Service England (NHS) coverage. 1,2 The technology has 32 regulatory approvals worldwide and is in various stages of research and development for nearly 170 diseases and conditions including Alzheimer’s disease, Parkinson’s disease, metastatic breast tumours, and tumours of the brain, liver, pancreas, and prostate. Launch of the UK FUSF will help enable donations to be applied directly to laboratory research and clinical trials in the UK, accelerating and expanding the exceptional work that has been ongoing for several years. It is hoped this will significantly increase the accessibility to already approved focused ultrasound-based treatments, which currently have limited availability in the UK. Specific areas of focus for the UK FUSF include cancer immunotherapy, brain diseases, pancreatic cancer, prostate cancer, and pediatric applications. “ Our vision at the Foundation is for focused ultrasound to be used in the UK to improve the lives of millions of people afflicted with a wide variety of serious medical disorders in the shortest time possible,” said Foundation Chairman Philip Keevil. “ By identifying opportunities, inspiring collaboration, raising awareness and overcoming barriers, the Foundation will shorten the time from laboratory research to widespread treatment using this remarkable and versatile technology.” The UK FUSF is an independent charity registered with the Charity Commission and HMRC, and GiftAid Eligible. It works closely with, but is independent of, the US-based Focused Ultrasound Foundation, aligning on goals and resources to advance focused ultrasound to treat millions worldwide. The Institute of Cancer Research in the UK was selected in 2013 by the US organization as the second global Focused Ultrasound “Center of Excellence” (there are now only 10 worldwide). UK FUSF is already partnering with the prostate cancer charity Prost8 UK and focused ultrasound device manufacturer Sonablate to increase access of focused ultrasound treatment for patients diagnosed with prostate cancer by co-funding the deployment early this year of a new prostate cancer treatment device at Guys & St Thomas' Hospital in London. “ I’ve been studying the use of focused ultrasound technology in oncology and have worked with the US Foundation for many years,” said Professor Gail ter Haar of The Institute of Cancer Research. “ The launch of the UK FUSF is an incredibly important milestone. This organisation will further catalyse development and adoption of the technology, bringing much needed innovative new treatments to our community and beyond.” The potential of focused ultrasound to be a game-changing treatment for so many diseases has attracted the attention of celebrities including musician Peter Gabriel, an honorary member of the UK FUSF Advisory Council. Said Mr. Gabriel, “ Sound has been the stuff I work with every day of my life. It’s thrilling to see how powerful it can be when ingeniously applied to healthcare. I’m delighted to see these pioneering technologies take root in the UK.” About the UK Focused Ultrasound Foundation Together with our sister organisation in the US, the UK Focused Ultrasound Foundation is working to provide patients with this noninvasive, life-changing treatment option in the shortest time possible. The UK FUSF will contribute financial and human resources to foster collaboration, to build knowledge and to streamline the process and overcome barriers. Focused ultrasound research in the UK has been funded by the US Foundation since 2009. For more information visit https://ukfusf.org/ . About Focused Ultrasound Focused ultrasound uses ultrasound energy guided by real-time imaging to treat tissue deep in the body without incisions or radiation. It is approved in the UK to treat prostate cancer and essential tremor. Dozens of additional indications are approved elsewhere in the world, including the United States, Europe and Asia. The technology is in various stages of research and development for nearly 170 diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, metastatic breast tumours, and tumours of the brain, liver and pancreas. Click here to watch a 6-minute video about focused ultrasound in the UK. References 1.National Institute for Health and Care Excellence 2005. High-intensity focused ultrasound for prostate cancer. Interventional procedures guidance [IPG118] . Available at: https://www.nice.org.uk/guidance/ipg118/chapter/1-Guidance . Last accessed January 2023. 2. National Institute for Health and Care Excellence 2018. Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor. Interventional procedures guidance [IPG617] . Available at: https://www.nice.org.uk/guidance/ipg617/chapter/1-Recommendations . Last accessed January 2023.

LONDON--( BUSINESS WIRE )--The UK Focused Ultrasound Foundation (UK FUSF), dedicated to advancing the development and adoption of focused ultrasound in the UK, today announced its formal launch. Focused ultrasound is a groundbreaking platform technology that uses ultrasound energy guided by real-time imaging to treat tissue deep in the body, without incisions or radiation. The Foundation will celebrate its launch with an event being held on 31 January at the House of Lords with important guests including MPs, members of the House of Lords, business leaders, and experts from medical charities and some of the UK’s leading research institutions, including the Institute of Cancer Research, Oxford University, and Imperial, King’s and University Colleges, London. Currently, focused ultrasound treatment for both prostate cancer and essential tremor has National Institute for Health and Care Excellence (NICE) approval and National Health Service England (NHS) coverage. 1,2 The technology has 32 regulatory approvals worldwide and is in various stages of research and development for nearly 170 diseases and conditions including Alzheimer’s disease, Parkinson’s disease, metastatic breast tumours, and tumours of the brain, liver, pancreas, and prostate. Launch of the UK FUSF will help enable donations to be applied directly to laboratory research and clinical trials in the UK, accelerating and expanding the exceptional work that has been ongoing for several years. It is hoped this will significantly increase the accessibility to already approved focused ultrasound-based treatments, which currently have limited availability in the UK. Specific areas of focus for the UK FUSF include cancer immunotherapy, brain diseases, pancreatic cancer, prostate cancer, and pediatric applications. “ Our vision at the Foundation is for focused ultrasound to be used in the UK to improve the lives of millions of people afflicted with a wide variety of serious medical disorders in the shortest time possible,” said Foundation Chairman Philip Keevil. “ By identifying opportunities, inspiring collaboration, raising awareness and overcoming barriers, the Foundation will shorten the time from laboratory research to widespread treatment using this remarkable and versatile technology.” The UK FUSF is an independent charity registered with the Charity Commission and HMRC, and GiftAid Eligible. It works closely with, but is independent of, the US-based Focused Ultrasound Foundation, aligning on goals and resources to advance focused ultrasound to treat millions worldwide. The Institute of Cancer Research in the UK was selected in 2013 by the US organization as the second global Focused Ultrasound “Center of Excellence” (there are now only 10 worldwide). UK FUSF is already partnering with the prostate cancer charity Prost8 UK and focused ultrasound device manufacturer Sonablate to increase access of focused ultrasound treatment for patients diagnosed with prostate cancer by co-funding the deployment early this year of a new prostate cancer treatment device at Guys & St Thomas' Hospital in London. “ I’ve been studying the use of focused ultrasound technology in oncology and have worked with the US Foundation for many years,” said Professor Gail ter Haar of The Institute of Cancer Research. “ The launch of the UK FUSF is an incredibly important milestone. This organisation will further catalyse development and adoption of the technology, bringing much needed innovative new treatments to our community and beyond.” The potential of focused ultrasound to be a game-changing treatment for so many diseases has attracted the attention of celebrities including musician Peter Gabriel, an honorary member of the UK FUSF Advisory Council. Said Mr. Gabriel, “ Sound has been the stuff I work with every day of my life. It’s thrilling to see how powerful it can be when ingeniously applied to healthcare. I’m delighted to see these pioneering technologies take root in the UK.” About the UK Focused Ultrasound Foundation Together with our sister organisation in the US, the UK Focused Ultrasound Foundation is working to provide patients with this noninvasive, life-changing treatment option in the shortest time possible. The UK FUSF will contribute financial and human resources to foster collaboration, to build knowledge and to streamline the process and overcome barriers. Focused ultrasound research in the UK has been funded by the US Foundation since 2009. For more information visit https://ukfusf.org/ . About Focused Ultrasound Focused ultrasound uses ultrasound energy guided by real-time imaging to treat tissue deep in the body without incisions or radiation. It is approved in the UK to treat prostate cancer and essential tremor. Dozens of additional indications are approved elsewhere in the world, including the United States, Europe and Asia. The technology is in various stages of research and development for nearly 170 diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, metastatic breast tumours, and tumours of the brain, liver and pancreas. Click here to watch a 6-minute video about focused ultrasound in the UK. References 1.National Institute for Health and Care Excellence 2005. High-intensity focused ultrasound for prostate cancer. Interventional procedures guidance [IPG118] . Available at: https://www.nice.org.uk/guidance/ipg118/chapter/1-Guidance . Last accessed January 2023. 2. National Institute for Health and Care Excellence 2018. Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor. Interventional procedures guidance [IPG617] . Available at: https://www.nice.org.uk/guidance/ipg617/chapter/1-Recommendations . Last accessed January 2023.

DUBLIN--( BUSINESS WIRE )--The "Global Prostate Cancer Minimally Invasive Surgery Market (2022-2027) by Product Type, Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Prostate Cancer Minimally Invasive Surgery Market is estimated to be USD 19.25 Bn in 2022 and is expected to reach USD 30.03 Bn by 2027, growing at a CAGR of 9.3%. Market dynamics are forces that impact the prices and behaviors of the Global Prostate Cancer Minimally Invasive Surgery Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals. As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding growth and reducing risks. Competitive Quadrant The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Ansoff Analysis The report presents a detailed Ansoff matrix analysis for the Global Prostate Cancer Minimally Invasive Surgery Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach. The analyst analyses the Global Prostate Cancer Minimally Invasive Surgery Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth. Why buy this report? The report offers a comprehensive evaluation of the Global Prostate Cancer Minimally Invasive Surgery Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies. The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry. The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report. The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies. The report also contains a competitive analysis using Positioning Quadrants, the analyst's competitive positioning tool. Market Dynamics Drivers Rising Prevalence of Prostate Cancer Along with Rapidly Aging Population Increasing Demand for Minimally Invasive Surgery Restraints Surgery Complications Opportunities Development of New Minimally Invasive Instruments Challenges Dearth of Skilled Personnel Market Segmentation The Global Prostate Cancer Minimally Invasive Surgery Market is segmented based on Product Type, Application, and Geography. By Product Type, the market is classified into Hand, Monitoring & Visualization, and Powered. By Application, the market is classified into Laparoscopy, Brachytherapy, and Cryosurgery. By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific. Companies Mentioned Accuray Inc. Bard Cancer Diagnostics Becton, Dickinson and Company Boston Scientific Corp. Eckert & Ziegler Ag EDAP TMS SA Elekta AB HealthTronics Inc. Intuitive Surgical Isoray Inc. Profound Medical Corp. Provision Healthcare Siemens Healthineers Ag SonaCare Medical LLC Theragenics Corp. Varian Medical Systems, Inc. For more information about this report visit https://www.researchandmarkets.com/r/6m46bu